Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MARVELD1 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
MARVELD1 siRNA is an experimental RNA interference (RNAi) therapeutic designed to silence the expression of the MARVEL domain-containing protein 1 (MARVELD1). MARVELD1 has been identified as a tumor stem cell marker and a potential therapeutic target, particularly in the context of visceral obesity-associated ovarian cancer. By utilizing the RNAi pathway, this agent triggers the sequence-specific degradation of MARVELD1 mRNA, thereby reducing the protein levels of MARVELD1. This knockdown is intended to inhibit tumor progression, stemness, and the aggressive phenotype of ovarian cancer cells associated with visceral obesity.
- Other names
- MARVELD1 small interfering RNAMARVELD-1 small interfering RNAMARVELD 1 small interfering RNAMARVEL domain-containing protein 1 siRNA
02
Targets
MenW-135 CPS (Neisseria meningitidis serogroup W-135 capsular polysaccharide)
Beyond the preview
Go deeper on MARVELD1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MARVELD1 siRNA.